Koide Laboratory - Synthetic Protein Science

We aim to advance the knowledge of how proteins and protein interaction networks work by “synthetic” approaches, i.e. designing and making proteins with novel function.  This "learning by building" approach critically tests our understanding of principles that govern protein structure, function and evolution, and it challenges our creativity.

We are now capable of producing highly functional synthetic proteins within weeks.  Structural and functional analysis of synthetic proteins not only critically evaluates the effectiveness of our design strategies but also provides broader insights into the molecular mechanism and evolution of protein form and function.  Knowledge gained from the synthetic approach complements and very often significantly expands the view from classical studies of natural proteins.

Synthetic proteins serve as novel and transformative tools for basic and translational research in medicine and beyond.  We are particularly interested in applying our capability to:

  • Development of biologics therapeutics (engineered proteins and antibodies)
  • Signal transduction and cancer biology
  • Structural biology
  • Synthetic biology

Why synthetic protein science?

News

Postdoctoral and Research Technologist positions available in developing biologics therapeutics - Contact Shohei Koide

April 2022 - Our review on engineering exquisite specificity is published in Methods Mol Biol.

April 2022 - Lauren successfully defended her Ph.D. thesis. Congrats, Dr. Wallon!

March 2022 - A multi-disciplinary collaboration among five labs at NYU School of Medicine and NYU Chemistry reveals a new way to inhibit MRSA. A new paper published in Nature Chemical Biology. Highlighed in News & Views and in NYU press release.

March 2022 - Our paper with Prof. Randy Stockbridge on cool protein engineering to repurpose a monobody crystallization chaperone for determing the long-sought-after crystal structures of EmrE with multiple ligands is published in Elife.

February 2022 - Our paper establishing the nucleotide-free RAS as a druggable target is published in Cell Reports. Our monobody technology played the crucial role in this discovery (again).

December 2021 - Our paper on the development of cytotoxic antibodies targeting CD99 for leukemia therapy is published in J Mol Biol.

September 2021 - A comprehensive review by Padma and Kevin on target validation with monobodies is published in RSC Med Chem.

August 2021 - A paper from a massive NYU-wide collaboration on the microbiome associated with COVID-19 infection is published in Nature Microbiology.

August 2021 - Lari has successfully defended her Ph.D. thesis. Congrats, Dr. Romero!

June 2021 - Our paper with Prof. S. Burden's group on antibody rescue of congenital myasthenia is published in Nature. The paper was highlighted in Nature Rev Drug Discovery.

May 2021 - Our paper on Monobodies that selectively inhibit and degrade KRAS(G12V) and KRAS(G12C) is published in Nature Comm.

May 2021 - Our paper with Prof. J. O'Bryan's group on the effect of NS1 Monobody on a mouse model of pancreatic cancer is published in Small GTPases.

April 2021 - Our second paper with Prof. J. Murphy's group on molecular dissection of the necroptosys signaling using MLKL-binding Monobodies is published in Nature Comm.